Customer support

xie@china-sinoway.com
EnglishEnglish
banner
Products
Home

API

Atracurium Besylate 64228-81-5

Atracurium Besylate 64228-81-5

96% up by HPLC, USP, GMP
  • Product Details

Product Information


Product name

Atracurium Besylate

CAS No.

64228-81-5

Molecular Formula

C53H72N2O12.2(C6H5O3S)

Molecular Weight

257.60

Quality Standard

96% up by HPLC, GMP,USP

Appearance

White or almost white powder


COA of Atracurium Besylate


ITEMS

SPECIFICATION

RESULT

Appearance:

white or almost white powder,

slightly hygroscopic, ordorless

 

 Confirms

Very solutable in acetonitrile or chloroform, Soluble in Water, very soluble and practically insolutable in ethyl ether

 Confirms

Identification

(1) IR

Conforms

 (2) HPLC

Conforms

Water

≤ 5.0%

0.6%

Residue on ignition

≤ 0.2%

0.1%

Methyl benzenesulfonate

≤ 0.1%

Undetected

Toluene

≤ 890ppm (ICH)

102ppm

Chromatographic purity

(1) Laudanosine: ≤ 0.5%

(2) Other individual impurities: ≤ 1.0%

(3) Total Impurities: ≤ 3.5%

0.01%

0.38%

1.3%

Isomer Ratio

Trans-Trans Isomer: 5%-6.5%

5.7%

 

Cis-Trans Isomer: 34.5%-38.5%

36%

 

Cis-Cis Isomer: 55%-60%

58.2%

Assay

96%-102%

  (C65H82N2O18S2 on anhydrous basis)

100.2%

Residue Solvents

(1) Dichloromethane: ≤ 600ppm

(2) Acctonitrile: ≤ 410ppm

(3) Ethyl ether: ≤ 5000ppm

Undetected

Undetected

1739ppm

Result

Confirms to USP34


Usage

Function of Atracurium Besylate

Atracurium besylate is a skeletal muscle relaxant for general anesthesia, suitable for the treatment of muscle relaxation for endotracheal intubation and for muscle relaxation required for thoracic and abdominal surgery. Like most neuromuscular blocking agents, it can Causes the release of histamine, skin flushing, transient hypotension, and occasionally bronchospasm. Caution should be used in patients with myasthenia gravis, neuromuscular disease, and severe electrolyte disturbances, as it potentiates the effects of other non-depolarizing agents. People with severe cardiovascular disease are more sensitive to the transient hypotensive reaction of this product, so it is recommended to give slow intravenous injection in divided doses.


*Products under the patent are only for R&D use

Send A Message

If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.
Related Products

Spironolactone
Spironolactone 52-01-7
EP8, USP38,99.95% up by HPLC, total impurities < 0.05%
Mupirocin powder
Mupirocin 12650-69-0
99% up by HPLC / GMP
Imatinib mesylate
Imatinib Mesylate 220127-57-1
In-house Standard
Ceftiofur sodium
Ceftiofur sodium 104010-37-9
In-house Specification
Thymopentin
Thymopentin 69558-55-0
99% up Medical Grade
Azilsartan
Azilsartan 147403-03-0
99% up, JP/ GMP / PMDA / DMF
Send A Message
Send A Message
If you are interested in our products and want to know more details,please leave a message here,we will reply you as soon as we can.

Home

Products

about

Contact